D
Donna Masterman
Researcher at Genentech
Publications - 22
Citations - 3659
Donna Masterman is an academic researcher from Genentech. The author has contributed to research in topics: Ocrelizumab & Interferon beta-1a. The author has an hindex of 12, co-authored 22 publications receiving 2871 citations. Previous affiliations of Donna Masterman include Amgen & Hoffmann-La Roche.
Papers
More filters
Journal Article
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001)
Xavier Montalban,Bernhard Hemmer,Kottil Rammohan,Gavin Giovannoni,Jérôme De Seze,Amit Bar-Or,Douglas L. Arnold,Annette Sauter,Donna Masterman,Paulo Fontoura,Hideki Garren,Peter Chin,Jerry S. Wolinsky +12 more
TL;DR: Ocrelizumab is the first investigational treatment to meet primary and key secondary efficacy outcomes in a Phase III PPMS study, and overall safety is satisfactory.
Journal Article
Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004)
Stephen L. Hauser,David K.B. Li,Peter A. Calabresi,Paul O'Connor,Amit Bar-Or,Frederik Barkhof,Annette Sauter,David Leppert,Donna Masterman,Jeroen Tinbergen,Ludwig Kappos +10 more
TL;DR: In this open-label extension study, patients followed for up to 72 weeks after last OCR dose experienced very little new MRI activity, low clinical disease activity, and no new safety concerns.
Journal Article
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)
Anthony Traboulsee,Douglas L. Arnold,Amit Bar-Or,Giancarlo Comi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Krzysztof Selmaj,Gaelle Klingelschmitt,Donna Masterman,Paulo Fontoura,Peter Chin,Hideki Garren,Stephen L. Hauser +13 more
TL;DR: Ocrelizumab consistently resulted in greater achievement of NEDA vs IFNβ-1a over 96 weeks, with elimination of new/enlarging T2 lesions in nearly all patients after week 24.
Journal ArticleDOI
P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFNβ-1a–controlled OPERA I and OPERA II studies
T. Ziemssen,Amit Bar-Or,Douglas L. Arnold,G. Comi,H.-P. Hartung,Stephen L. Hauser,Fred D. Lublin,K. Selmaj,Anthony Traboulsee,Peter Chin,Paulo Fontoura,Hideki Garren,Donna Masterman,Ludwig Kappos +13 more
TL;DR: Ab titers against common viral and bacterial antigens were similar between the IFN β -1a and OCR groups at baseline and were maintained during the 96-week study treatment period, and treatment with OCR does not appear to affect preexisting humoral immunity.
Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
Jerry S. Wolinsky,Douglas L. Arnold,Amit Bar-Or,J. de Seze,Gavin Giovannoni,B. Hemmer,Kottil Rammohan,Annette Sauter,Donna Masterman,Paulo Fontoura,Hideki Garren,Peter Chin,Xavier Montalban +12 more